Advertisement
| car t therapy for ms: HIV-1 Latency Guido Silvestri, Mathias Lichterfeld, 2018-10-11 This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public. |
| car t therapy for ms: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t therapy for ms: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t therapy for ms: Moderate to Severe Psoriasis John Koo, Jashin Wu, Alice Gottlieb, Ethan Levin, Argentina Leon, 2014-03-18 Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis |
| car t therapy for ms: Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases Richard K. Burt, Dominique Farge, Milton A. Ruiz, Riccardo Saccardi, John A. Snowden, 2021-11-17 This book summarizes the global progress in medical and scientific research toward converting traditionally chronic autoimmune diseases into a drug-free reversible illness using hematopoietic stem cell transplantation (HSCT) and other cellular therapies such as T regulatory cells (Treg), mesenchymal stromal/stem cells, and chimeric antigen receptor T (CAR T) cells in order to reintroduce sustained immune tolerance. This title provides information on different types of stem cells and immune cells; post-transplant immune regeneration; cellular regulatory requirements; ethical and economic considerations; and the advantages and disadvantages of HSCT in the treatment of a variety of autoimmune diseases versus current conventional treatments. Arranged by disease, the text provides a comprehensive guide to HSCT for all types of autoimmune/immune disorders including monogenetic autoimmune diseases; autoimmune aplastic anemia; neurologic immune diseases including multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, neuromyelitis optica, and stiff person syndrome; rheumatologic diseases such as systemic sclerosis and systemic lupus erythematosus; dermatologic diseases such as pemphigus; gastrointestinal disorders such as Crohn’s disease and celiac disease; and immune-mediated endocrinologic disease type I diabetes mellitus. Guidance is provided on the transplantation technique, cell collection and processing, conditioning regimens, infections, and early and late complications. Key Features Outlines therapies and techniques for HSCT for autoimmune diseases Discusses the advantages of HSCT over conventional therapies Reviews the entire process of stem cell therapy from harvest and ethics to indications, efficacy, and regulatory oversight |
| car t therapy for ms: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| car t therapy for ms: Neurodegeneration in Multiple Sclerosis M. Filippi, M. Rovaris, G. Comi, 2008-02-01 Written by world-renowned scientists, the volume provides a state-of-the-art on the most recent MRI techniques related to MS, and it is an indispensable tool for all those working in this field. The context in which this book exists is that there is an increasing perception that modern MR methodologies should be more extensively employed in clinical trials to derive innovative information. |
| car t therapy for ms: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t therapy for ms: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| car t therapy for ms: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t therapy for ms: Cancer and the Heart Michael S. Ewer, 2013 The book begins with the basic science behind the medical applications of the knowledge: cardiovascular biology, pathways, and their relationship to cancer treatment and principles of chemotherapy and immunotherapy. The second section consists of an overview and classification of anti-cancer drugs and a look at their cardiotoxicity. The third section looks at cardiac imaging in the cancer patient, including cardiac ultrasound, Doppler imaging, nuclear imaging, magnetic resonance imaging, and computed tomography in the cancer patient. In section four, management of cardiac disease in the cancer patient is discussed, including cardiac rhythm disturbances and heart failure. Cardiac emergencies and interventions are described as is preoperative assessment of the cancer patient for non- cardiovascular surgery. The final section includes a range of topics such as the pericardium, cardiovascular effects of endocrine treatments, primary cardiac tumors and malignancies of the myocardium and pericardium. Cardiac monitoring during clinical trials and pulmonary concerns are also addressed, as are psychosocial, social, economic, and legal issues of the cancer patient with heart disease. |
| car t therapy for ms: Ask a Manager Alison Green, 2018-05-01 From the creator of the popular website Ask a Manager and New York’s work-advice columnist comes a witty, practical guide to 200 difficult professional conversations—featuring all-new advice! There’s a reason Alison Green has been called “the Dear Abby of the work world.” Ten years as a workplace-advice columnist have taught her that people avoid awkward conversations in the office because they simply don’t know what to say. Thankfully, Green does—and in this incredibly helpful book, she tackles the tough discussions you may need to have during your career. You’ll learn what to say when • coworkers push their work on you—then take credit for it • you accidentally trash-talk someone in an email then hit “reply all” • you’re being micromanaged—or not being managed at all • you catch a colleague in a lie • your boss seems unhappy with your work • your cubemate’s loud speakerphone is making you homicidal • you got drunk at the holiday party Praise for Ask a Manager “A must-read for anyone who works . . . [Alison Green’s] advice boils down to the idea that you should be professional (even when others are not) and that communicating in a straightforward manner with candor and kindness will get you far, no matter where you work.”—Booklist (starred review) “The author’s friendly, warm, no-nonsense writing is a pleasure to read, and her advice can be widely applied to relationships in all areas of readers’ lives. Ideal for anyone new to the job market or new to management, or anyone hoping to improve their work experience.”—Library Journal (starred review) “I am a huge fan of Alison Green’s Ask a Manager column. This book is even better. It teaches us how to deal with many of the most vexing big and little problems in our workplaces—and to do so with grace, confidence, and a sense of humor.”—Robert Sutton, Stanford professor and author of The No Asshole Rule and The Asshole Survival Guide “Ask a Manager is the ultimate playbook for navigating the traditional workforce in a diplomatic but firm way.”—Erin Lowry, author of Broke Millennial: Stop Scraping By and Get Your Financial Life Together |
| car t therapy for ms: CDC Yellow Book 2018: Health Information for International Travel Centers for Disease Control and Prevention CDC, 2017-04-17 THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad. |
| car t therapy for ms: Multiple Sclerosis Institute of Medicine, Board on Neuroscience and Behavioral Health, Committee on Multiple Sclerosis: Current Status and Strategies for the Future, 2001-08-10 Multiple sclerosis is a chronic and often disabling disease of the nervous system, affecting about 1 million people worldwide. Even though it has been known for over a hundred years, no cause or cure has yet been discovered-but now there is hope. New therapies have been shown to slow the disease progress in some patients, and the pace of discoveries about the cellular machinery of the brain and spinal cord has accelerated. This book presents a comprehensive overview of multiple sclerosis today, as researchers seek to understand its processes, develop therapies that will slow or halt the disease and perhaps repair damage, offer relief for specific symptoms, and improve the abilities of MS patients to function in their daily lives. The panel reviews existing knowledge and identifies key research questions, focusing on: Research strategies that have the greatest potential to understand the biological mechanisms of recovery and to translate findings into specific strategies for therapy. How people adapt to MS and the research needed to improve the lives of people with MS. Management of disease symptoms (cognitive impairment, depression, spasticity, vision problems, and others). The committee also discusses ways to build and financially support the MS research enterprise, including a look at challenges inherent in designing clinical trials. This book will be important to MS researchers, research funders, health care advocates for MS research and treatment, and interested patients and their families. |
| car t therapy for ms: Neuroimmunological Diseases Susumu Kusunoki, 2016-06-24 This book offers a detailed review of the remarkable advances that have been made in research on the pathogenesis of a number of neuroimmunological diseases, as well as outlining novel treatments including the use of monoclonal antibodies. Written by renowned experts who have made major contributions in the field, such as identifying neuromyelitis optica as an immunopathological clinical condition, identifying the role of ganglioside and ganglioside-complex antibodies in Guillain-Barré syndrome, and developing a novel treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, the book summarizes recent advances in basic and clinical research. Neuroimmunological Diseases is a useful resource for not only researchers but also neurologists who are engaged in the management of neuroimmunological diseases. |
| car t therapy for ms: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
| car t therapy for ms: Diseases of the Brain, Head and Neck, Spine 2020–2023 Juerg Hodler, Rahel A. Kubik-Huch, Gustav K. von Schulthess, 2020-02-14 This open access book offers an essential overview of brain, head and neck, and spine imaging. Over the last few years, there have been considerable advances in this area, driven by both clinical and technological developments. Written by leading international experts and teachers, the chapters are disease-oriented and cover all relevant imaging modalities, with a focus on magnetic resonance imaging and computed tomography. The book also includes a synopsis of pediatric imaging. IDKD books are rewritten (not merely updated) every four years, which means they offer a comprehensive review of the state-of-the-art in imaging. The book is clearly structured and features learning objectives, abstracts, subheadings, tables and take-home points, supported by design elements to help readers navigate the text. It will particularly appeal to general radiologists, radiology residents, and interventional radiologists who want to update their diagnostic expertise, as well as clinicians from other specialties who are interested in imaging for their patient care. |
| car t therapy for ms: Multiple Sclerosis and Related Disorders Robert J. Fox, MD, Alexander D. Rae-Grant, MD, Francois Bethoux, MD, 2018-08-28 Revised and updated second edition of Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation, the only comprehensive but practical source of core information on multiple sclerosis and other demyelinating disorders. Intended as a ready reference for clinicians who provide ongoing care to MS patients, this book combines evidence-based science with experience-based guidance to present current standards and management protocols from leading MS centers. Beginning with the scientific underpinnings of MS for clinicians, the book proceeds through diagnosis, including initial symptoms, diagnostic criteria and classification, imaging, and differential diagnosis, and onto approved treatments for the various MS types and emerging therapies. Later parts of the book discuss symptom management and rehabilitation with chapters focusing on specific side effects, along with considerations for special populations, comorbidities, societal and family issues, and related autoimmune disorders that are often mistaken for MS. Throughout, chapters include lists of Key Points both for clinicians and for patients and families, and management pearls are boxed for quick reference and clinical utility. Illustrations, tables, algorithms, assessment scales, and up-to-date MRI imaging enrich the text, making this a wide-ranging clinical reference for all members of the MS care team. New to the Second Edition: Includes summary recommendations from new AAN practice guidelines for use of DMTs All chapters updated to reflect the latest literature and diagnostic criteria Five entirely new chapters added to expand coverage of treatment, rehabilitation and symptom management, and special issues related to MS Treatment section has been completely revised to better capture current approaches to disease modifying therapies, with separate chapters devoted to injection and oral therapies, infusion therapies, and treatments for progressive forms of MS Related autoimmune diseases section significantly expanded to include transverse myelitis, autoimmune encephalitis, and neurosarcoidosis |
| car t therapy for ms: Drug Resistance in Leukemia & Gert-Jan L. Kaspers, 1993-01-01 The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols. |
| car t therapy for ms: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| car t therapy for ms: Biological Collections National Academies of Sciences, Engineering, and Medicine, Division on Earth and Life Studies, Board on Life Sciences, Committee on Biological Collections: Their Past, Present, and Future Contributions and Options for Sustaining Them, 2021-01-29 Biological collections are a critical part of the nation's science and innovation infrastructure and a fundamental resource for understanding the natural world. Biological collections underpin basic science discoveries as well as deepen our understanding of many challenges such as global change, biodiversity loss, sustainable food production, ecosystem conservation, and improving human health and security. They are important resources for education, both in formal training for the science and technology workforce, and in informal learning through schools, citizen science programs, and adult learning. However, the sustainability of biological collections is under threat. Without enhanced strategic leadership and investments in their infrastructure and growth many biological collections could be lost. Biological Collections: Ensuring Critical Research and Education for the 21st Century recommends approaches for biological collections to develop long-term financial sustainability, advance digitization, recruit and support a diverse workforce, and upgrade and maintain a robust physical infrastructure in order to continue serving science and society. The aim of the report is to stimulate a national discussion regarding the goals and strategies needed to ensure that U.S. biological collections not only thrive but continue to grow throughout the 21st century and beyond. |
| car t therapy for ms: Clinical Neuroimmunology Jack P. Antel, 2005 Clinical Neurimmunology is the major reference text in the field, providing broad and comprehensive coverage of the interaction between the nervous and immune systems in both normal and diseased states. Understanding this interaction is fundamental to developing therapeutic approaches to disease and injury of the nervous system that are currently only marginally amenable to therapy. Neuroimmunology is a well-recognised and growing specialty world wide, both at the basic science and clinical level. It is a fast moving field and this is the most up to date text available. Chapters are dedicated to the role of the immune system in disorders affecting both the central and peripheral nervous systems, including important neurodegenerative diseases (such as multiple sclerosis and HIV-related neural degeneration) which cause life-long disability. Extensive coverage is given to a whole array of immune-directed therapies. The book has a strong international team of well respected, high profile editors and authors. The first edition published to extensive and positive reviews and has established itself as the principal reference source in the field. This second edition summarizes recent advances in clinical neuroimmunology in a comprehensive and unbiased way. |
| car t therapy for ms: Human B Cell Populations Manlio Ferrarini, Federico Caligaris-Cappio, 1997-01-01 B cells used to be considered as a homogeneous population of cells destined to produce antibodies of increasing affinity and to maintain an immunological memory. In recent years, it has been determined that B cells can be subdivided into different subsets characterized by distinct morphologic, phenotypic, and functional features. Presenting results of research work on the definition of B cell subset populations, this book explains the basic mechanisms that control B cell activation, stimulation and regulation. Articles include studies on both normal and malignant B cells and describe the mechanisms underlying T-B cell interactions during the immune response. The most important advances in the field of immunodeficiency are also reported. This volume will be essential not only for basic and clinical immunologists, but also for hematologists, pathologists and rheumatologists with a special interest in the pathogenesis of lymphoproliferative or autoimmune disorders. |
| car t therapy for ms: Oncology Nutrition for Clinical Practice Anne Coble Voss, Valaree Williams, 2021 A comprehensive reference for professionals providing up-to-date oncology nutrition practice recommendations, the latest nutrition assessment tools, current knowledge, and support and resources-- |
| car t therapy for ms: How Stella Learned to Talk Christina Hunger, 2021-05-04 INSTANT NEW YORK TIMES BESTSELLER An incredible, revolutionary true story and surprisingly simple guide to teaching your dog to talk from speech-language pathologist Christina Hunger, who has taught her dog, Stella, to communicate using simple paw-sized buttons associated with different words. When speech-language pathologist Christina Hunger first came home with her puppy, Stella, it didn’t take long for her to start drawing connections between her job and her new pet. During the day, she worked with toddlers with significant delays in language development and used Augmentative and Alternative Communication (AAC) devices to help them communicate. At night, she wondered: If dogs can understand words we say to them, shouldn’t they be able to say words to us? Can dogs use AAC to communicate with humans? Christina decided to put her theory to the test with Stella and started using a paw-sized button programmed with her voice to say the word “outside” when clicked, whenever she took Stella out of the house. A few years later, Stella now has a bank of more than thirty word buttons, and uses them daily either individually or together to create near-complete sentences. How Stella Learned to Talk is part memoir and part how-to guide. It chronicles the journey Christina and Stella have taken together, from the day they met, to the day Stella “spoke” her first word, and the other breakthroughs they’ve had since. It also reveals the techniques Christina used to teach Stella, broken down into simple stages and actionable steps any dog owner can use to start communicating with their pets. Filled with conversations that Stella and Christina have had, as well as the attention to developmental detail that only a speech-language pathologist could know, How Stella Learned to Talk will be the indispensable dog book for the new decade. |
| car t therapy for ms: T Cell Clones Harald von Boehmer, Werner Haas, 1985 |
| car t therapy for ms: Emerging Learnings in Cell Therapy: Novel Binding Domains, Universal CAR-T Cells, and More Anand Rotte, Matthew John Frigault, Binod Dhakal , Christopher Heery, 2024-04-22 The Past decade has seen significant advances in cancer immunotherapy with the development of multiple strategies including monoclonal antibodies targeting checkpoint blockers, oncolytic viruses, fusion proteins and cell therapies such as tumor-specific chimeric antigen receptor (CAR-) T cell therapy, NK cell therapy and γδ-T-cell therapy. Multiple cell therapies including sipuleucel-T (Provange), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), tisagenlecleucel (Kymriah), lisocabtagene maraleucel (Breyanzi), idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) have been approved by the US FDA for different hematological cancers and hormone-refractory prostate cancer (Provange). Impressive results were noted with CAR-T cell therapy with objective response rates (ORR) as high as 100% in certain hematological cancers and with responses durable over 10 years in some patients. |
| car t therapy for ms: CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book Caron A Jacobson, Parth S. Shah, 2023-10-12 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| car t therapy for ms: Engineered immune cells in cancer immunotherapy (EICCI) Cristina Maccalli, Axel Schambach, Francisco Martin, Cameron Turtle, 2023-02-28 |
| car t therapy for ms: Medical Masterclass John D. Firth, Sivakumar Sathasivam, Greg Heath, David Horton, 2018 |
| car t therapy for ms: The Novel Engineering Strategies and Clinical Progress of Solid Tumor in CAR-T Cell Therapy Ken Young, Zheming Lu, Wenbin Qian, 2022-08-18 |
| car t therapy for ms: Adoptive cellular therapies in immunoregulation and cancer "Patrick" Peishun Shou, Chunliang Xu, Song Zhang, 2023-07-05 |
| car t therapy for ms: CAR-T Cell Therapies for Non-Hematopoietic Malignancies: Taking Off The Training Wheels Avery Dexter Posey, Jr., John - Maher, Marcela V. Maus, 2020-04-24 Chimeric antigen receptor (CAR) T cell therapies for leukemia (e.g. tisagenlecleucel) and lymphoma (e.g. axicabtagene ciloleucel) have recently received regulatory approval in the United States. Phase I/II trials have demonstrated complete remission of refractory or relapsed tumors in 50% - 94% patients. However, the clinical successes of engineered T cells for the treatment of solid malignancies have thus far been few and far between. Furthermore, several instances of severe and lethal toxicities have arisen due to on-target, off-tumor recognition of antigen by T cell products. Recent advances in phase I trials for solid tumors, as well as in pre-clinical models, have revealed several variables that will be important to consider for the successful use of CAR-T cells in treating solid tumors. These variables include (i) regional versus systemic delivery; (ii) scFv versus ligand interactions; (iii) antigen loss versus escape; (iv) epitope spreading and (v) checkpoint expression on immune cells or tumor cells. Also, there remains outstanding mechanistic questions related to why differences exist in the persistence and tonic signaling of second-generation CD28 versus 4-1BB co-stimulated CAR-T cells. In addition, we are now learning the roles of lympho-depleting regimens (and associated toxicities) in modifying the persistence of engineered T cell therapies. A more comprehensive view of CAR-T cell strategies and important advances, both of pre-clinical and clinical evaluations, in solid tumors is necessary to drive these therapies forward. |
| car t therapy for ms: Breakthrough in Immunotherapy Baptiste Durand, Anders Olofson, Thomas Clark, 2024-08-22 |
| car t therapy for ms: Cancer Treatment: An Interdisciplinary Approach Nima Rezaei, 2024-01-01 Cancer treatment is a challenging issue, while the treatment modalities have extended from traditional surgery, chemotherapy, and radiation therapy to new therapeutic approaches, including targeted therapy, immunotherapy, stem cell transplantation, and hormone therapy. Therefore, an interdisciplinary approach is needed to find a better therapeutic protocols in order to increase the prognosis and quality of life of patients with cancer. The second volume of the “Interdisciplinary Cancer Research” series, entitled “Cancer Treatment: An Interdisciplinary Approach” publishes comprehensive volumes on different cancer treatment modalities and presents the most updated and peer-reviewed articles on cancer therapy. This interdisciplinary series is of special value to researchers and practitioners working on cell biology, immunology, hematology, biochemistry, genetics, oncology and related fields. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for researchers and clinicians who wish to extend their knowledge on cancer treatment. |
| car t therapy for ms: Anti-tumor Activity of Cytotoxic Immune Cells: Basic Research and Clinical Perspectives Malgorzata Firczuk , Magdalena Winiarska, 2024-05-24 Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells are powerful effectors of antitumor immunity. CTL recognize tumor antigens presented by human leukocyte antigen (HLA) molecules with antigen-specific T cell receptors (TCR) and are the key effector cells of the adaptive immune response. In contrast, NK cells lack antigen-specific receptors and are regulated by the balance of signals from activating and inhibitory receptors. These two types of cells cooperate and complement each other in eliciting host immune response to cancer and mediating immune surveillance. Moreover, these cells play a crucial role in antitumor immunotherapy, including monoclonal antibodies (mAbs), bispecific T cell engagers (BiTe), as well as adoptive transfer of chimeric antigen receptor (CAR)-modified cytotoxic cells. |
| car t therapy for ms: Novel therapies for indolent lymphomas in the cellular therapy era Narendranath Epperla, Sairah Ahmed, 2023-11-06 |
| car t therapy for ms: Hematological Cancer Diagnosis and Treatment: An Interdisciplinary Approach Nima Rezaei, |
| car t therapy for ms: MCB: CAR T Cells: Development, Characterization and Applications Lorenzo Galluzzi, Sheila Spada, 2022-02-11 MCB: CAR T Cells: Development, Characterization and Applications, Volume 167 in the Methods in Cell Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR T-cell therapy, Determination of the Biodistribution of Chimeric Antigen Receptor-Modified T Cells against CD19 in NSG Mice, Generation of CAR-T cells using lentiviral vectors, Generation of CAR T-cells using ?-retroviral vector, Flow cytometry detection and quantification of CAR T cells into solid tumors, Evaluation of CAR-T Cell Cytotoxicity: Real-Time Impedance-Based Analysis, and much more. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the Methods in Cell Biology series - Includes the latest information on the topic of development, characterization and applications in CAR T Cells |
| car t therapy for ms: Engineered Targeted Cancer Immunotherapies Massimo Fantini, Roberto Bei, 2022-08-01 |
CD19-targeted chimeric antigen receptor T cell therapy in
CD19 chimeric antigen receptor (CAR)-T cell therapies have revolutionized the field of hematologic malignancies and have begun to demonstrate curative poten-tial use in …
CAR-T Therapy - ECPC
CAR-T cells are genetically modified T-cells which express a CAR corresponding to a specific tumour antigen, thus making it able to recognize and target tumour cells exclusively, unlike …
Clinical Development of Chimeric Antigen Receptor (CAR)-T …
CAR T-Cell Therapy Applications in OTAT *Current as of 01/01/2022. Antigen Targets • Approximately 274 CAR T cell INDs* – 64% are for hematologic malignancies – 86% are …
Manufacturing of CD19/20 Bispecific CAR T-Cell Therapy …
May 20, 2024 · Here, we evaluate IMPT-514, a bispecific CD19/CD20 CAR T-cell therapy product candidate, as a potential treatment for MS to deplete CD20+ T-cells and CD19+ or CD20+ …
Clinical Pharmacological Considerations on Car-T Cells …
CAR-T cell therapy exploits the normal T cell functions, which enables recognizing and eliminating infected and malignant cells, yet with anticipated higher specificity.
Delivering progress on a cellular level - Bristol Myers Squibb
Our CD19-directed CAR T cell therapy is an important option for patients with a broad array of relapsed/refractory B cell-mediated lymphomas. To date, more than 10,000 patients have been …
Immunotherapy: How CAR T-Cell Therapy Works for Cancer …
Identify implications for the use of CAR T-cell therapy for treatment of leukemia and lymphoma. Understand the process of how CAR T-cell treatment is administered. Describe the major …
Department of Health Care Services - DHCS
19 (CD19)-directed genetically modified autologous T-cell immunotherapy. This involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor …
MS-DRG 018 Chimeric Antigen Receptor T-cell (CAR-T) …
ASH supports CMS’ efforts to assure Medicare beneficiary access to CAR-T therapies by creating MS-DRG 018 and developing a payment methodology to recognize the high costs associated …
CD19 CAR T cells for multiple sclerosis: Forging further into …
Fischbach et al.1 report on the use of CD19 CAR T cells in two pa-tients with progressive multiple sclerosis, demonstrating feasibility and safety for the first time in this disease process.
The Economics of CAR T-Cell Therapy - accc-cancer.org
Chimeric antigen receptor (CAR) T-cell therapy is a rapidly growing area of oncology that has been transforming cancer care since its initial approval for acute lymphoblastic leukemia in 2017.
ASCO Management of Immune-Related Adverse Events in …
Nov 1, 2021 · PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with …
Chimeric Antigen Receptor (CAR) T-Cells - Cancer
Chimeric antigen receptor (CAR) T-cells are infection and disease fighting white blood cells that have been collected from your immune system and changed in a lab to target and help fight …
Frontiers in CAR-T cell therapy for autoimmune diseases - Cell …
May 30, 2024 · Currently, the US Food and Drug Administration (FDA) has ap-proved six CAR-T cell therapies designed to treat ten types of blood cancer, including diffuse large B cell …
CAR T-Cell Therapy for Your Patients: What You Need To Know
• Describe the MOA of Chimeric Antigen Receptor T-cell (CAR-T) therapy and approved-FDA indications • Understand where CAR-T therapy might fit into the cancer care landscape and its …
Multiple Signaling Roles of CD3ε and Its Application in CAR-T …
CD3ε promoted CAR-T persistence via p85 recruitment. Collectively, CD3ε is a built-in multifunctional signal tuner, and increasing CD3 diversity represents a strategy to design next …
Evaluating the Role of CAR-T Cell Therapy in the Context of …
is a need for a better understanding of how CAR -T cell therapy is best used in the context of available therapies. CAR -T Cell Therapy CAR -T cell therapies have been added to the …
Chimeric Antigen Receptor T-Cell Therapy in Chronic …
CAR T-Cell Therapy-Associated Cytokine Release Syndrome (CRS) CRS —May be mild or life-threatening •Occurs with CART19 activation and expansion •Dramatic cytokine elevations (IL …
Are CAR T cells the answer to myasthenia gravis therapy?
(CAR) T-cell therapy approach. 7. CAR T cells are a new class of molecularly precise therapies that are becoming increasingly established via their use in the treatment of advanced cancers. …
CAR T-Cell Therapy in Action: Successful Examples in …
CAR T-cell therapy, patients must have must have someone who is able to spend 24 hours per day with them to monitor vitals and accompany them to the cancer center as needed.
CD19-targeted chimeric antigen receptor T cell therapy in
CD19 chimeric antigen receptor (CAR)-T cell therapies have revolutionized the field of hematologic malignancies and have begun to demonstrate curative poten-tial use in …
CAR-T Therapy - ECPC
CAR-T cells are genetically modified T-cells which express a CAR corresponding to a specific tumour antigen, thus making it able to recognize and target tumour cells exclusively, unlike …
Clinical Development of Chimeric Antigen Receptor (CAR)-T …
CAR T-Cell Therapy Applications in OTAT *Current as of 01/01/2022. Antigen Targets • Approximately 274 CAR T cell INDs* – 64% are for hematologic malignancies – 86% are …
Manufacturing of CD19/20 Bispecific CAR T-Cell Therapy …
May 20, 2024 · Here, we evaluate IMPT-514, a bispecific CD19/CD20 CAR T-cell therapy product candidate, as a potential treatment for MS to deplete CD20+ T-cells and CD19+ or CD20+ …
Clinical Pharmacological Considerations on Car-T Cells …
CAR-T cell therapy exploits the normal T cell functions, which enables recognizing and eliminating infected and malignant cells, yet with anticipated higher specificity.
Delivering progress on a cellular level - Bristol Myers Squibb
Our CD19-directed CAR T cell therapy is an important option for patients with a broad array of relapsed/refractory B cell-mediated lymphomas. To date, more than 10,000 patients have …
Immunotherapy: How CAR T-Cell Therapy Works for Cancer …
Identify implications for the use of CAR T-cell therapy for treatment of leukemia and lymphoma. Understand the process of how CAR T-cell treatment is administered. Describe the major …
Department of Health Care Services - DHCS
19 (CD19)-directed genetically modified autologous T-cell immunotherapy. This involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor …
MS-DRG 018 Chimeric Antigen Receptor T-cell (CAR-T) …
ASH supports CMS’ efforts to assure Medicare beneficiary access to CAR-T therapies by creating MS-DRG 018 and developing a payment methodology to recognize the high costs associated …
CD19 CAR T cells for multiple sclerosis: Forging further into …
Fischbach et al.1 report on the use of CD19 CAR T cells in two pa-tients with progressive multiple sclerosis, demonstrating feasibility and safety for the first time in this disease process.
The Economics of CAR T-Cell Therapy - accc-cancer.org
Chimeric antigen receptor (CAR) T-cell therapy is a rapidly growing area of oncology that has been transforming cancer care since its initial approval for acute lymphoblastic leukemia in 2017.
ASCO Management of Immune-Related Adverse Events in …
Nov 1, 2021 · PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with …
Chimeric Antigen Receptor (CAR) T-Cells - Cancer
Chimeric antigen receptor (CAR) T-cells are infection and disease fighting white blood cells that have been collected from your immune system and changed in a lab to target and help fight …
Frontiers in CAR-T cell therapy for autoimmune diseases
May 30, 2024 · Currently, the US Food and Drug Administration (FDA) has ap-proved six CAR-T cell therapies designed to treat ten types of blood cancer, including diffuse large B cell …
CAR T-Cell Therapy for Your Patients: What You Need To …
• Describe the MOA of Chimeric Antigen Receptor T-cell (CAR-T) therapy and approved-FDA indications • Understand where CAR-T therapy might fit into the cancer care landscape and its …
Multiple Signaling Roles of CD3ε and Its Application in CAR …
CD3ε promoted CAR-T persistence via p85 recruitment. Collectively, CD3ε is a built-in multifunctional signal tuner, and increasing CD3 diversity represents a strategy to design next …
Evaluating the Role of CAR-T Cell Therapy in the Context of …
is a need for a better understanding of how CAR -T cell therapy is best used in the context of available therapies. CAR -T Cell Therapy CAR -T cell therapies have been added to the …
Chimeric Antigen Receptor T-Cell Therapy in Chronic …
CAR T-Cell Therapy-Associated Cytokine Release Syndrome (CRS) CRS —May be mild or life-threatening •Occurs with CART19 activation and expansion •Dramatic cytokine elevations (IL …
Are CAR T cells the answer to myasthenia gravis therapy?
(CAR) T-cell therapy approach. 7. CAR T cells are a new class of molecularly precise therapies that are becoming increasingly established via their use in the treatment of advanced cancers. …
CAR T-Cell Therapy in Action: Successful Examples in …
CAR T-cell therapy, patients must have must have someone who is able to spend 24 hours per day with them to monitor vitals and accompany them to the cancer center as needed.
